Tips from Other Journals

HPV Vaccine Shows Promise, at Least in Short Term



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2006 Sep 1;74(5):836-838.

Persistent infection with human papilloma-virus (HPV) types 16 or 18 may be the major cause of cervical cancer. Initial studies of vaccines against HPV 16 and 18 indicate that 90 percent of infections can be prevented, but long-term immunogenicity is required to prevent malignant change. Harper and colleagues studied participants in a randomized controlled trial of HPV vaccines to determine the long-term effectiveness and safety of these vaccines.

The study included 776 women who received three doses of the bivalent HPV-16/18 virus-like particle AS04 vaccine or a placebo. During the follow-up period, the researchers monitored cervical sampling for HPV DNA testing, cervical cytology, and blood tests for immunologic responses. Colposcopy was performed if two specimens had atypical squamous cells of undetermined significance or if they had low-grade squamous intraepithelial lesions. Participants also reported any new onset of chronic disease, any condition that required a consultation by a physician or hospital admission, or any serious adverse effect experienced during the follow-up study. The average follow-up lasted 47.7 months.

In the treated group, the mean HPV-16 and HPV-18 titers peaked one month after the third immunization but slowly declined to a stable plateau at 18 months. Patients showed a strong positive immunologic response. However, after HPV-16 and HPV-18 infection, the mean titers were 36.3 and 26.5 units per mL, respectively. Following immunization, the mean titers were 17-fold and 14-fold higher in HPV-16 and HPV-18 infections, respectively, than for naturally acquired infection. The authors stress that the immunization was effective for preventing new infections.

By intention-to-treat analyses, only two out of 353 immunized women developed new HPV-16 infections, and two out of 352 women taking the placebo developed new mixed HPV-16/18 infections during the extended follow-up. In women assigned to placebo, the following new infections were documented: HPV-16, 21 infections; HPV-18, 11 infections; mixed HPV-16 and HPV-18, 28 infections. The authors calculated that the effectiveness of the vaccine was 95.8 percent against new HPV-16 infections, 100 percent against new HPV-18 infections, and 96.9 percent against mixed infections. The vaccine also showed similar effectiveness against both incident and persistent infections. Adverse events were more common in the placebo group than in the vaccine group (22 percent versus 14 percent), but the researchers note that minimal adverse events were not related to the immunization.

The authors conclude that the immunization provided effective protection against HPV-16 and HPV-18 infections. The degree of protection exceeded expectations and may be attributed to additional protection against other oncogenic HPV types such as HPV-45 and HPV-31. The vaccine protection appears to last for four to five years.

Harper DM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. April 15, 2006;367:1247–55.

editor’s note: The authors ended their article by saying that their findings will set the stage for a worldwide adoption of human papillomavirus (HPV) vaccinations that will help prevent cervical cancer. Some gynecology journals already carry advertisements for a quadrivalent HPV vaccine against types 6, 11, 16, and 18. With 10,370 new cases a year and 3,710 women in the United States still dying from this disease annually,1 an HPV vaccination seems to be an obvious addition to a routine immunization schedule; however, it is not that straightforward. The oncogenic viruses most likely are acquired by sexual intercourse, and the risk of infection is related to the number of sexual partners as well as other factors. Immunizing all young persons before sexual activity could be interpreted as accepting or acknowledging that they are likely to follow risky sexual practices. Attempting to screen for persons most at risk raises many problems, including confidentiality, stigmatization, or a perceived “license for promiscuity.” Selective immunization does not protect the monogamous woman whose partner carries an oncogenic strain. Immunization against cervical cancer promises to be a difficult issue for individuals, families, couples, health care professionals, insurers, and policy makers. We can provide the protection, and 3,710 deaths each year is a high price to pay for avoiding difficult issues.—a.d.w.

 

REFERENCE

1. Moore DH. Cervical cancer. Obstet Gynecol. 2006;107:1152–61.



Copyright © 2006 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

Navigate this Article